Literature DB >> 29547088

Usefulness of the convexity apparent hyperperfusion sign in 123I-iodoamphetamine brain perfusion SPECT for the diagnosis of idiopathic normal pressure hydrocephalus.

Takuma Ohmichi1, Masaki Kondo1, Masahiro Itsukage1, Hidetaka Koizumi1, Shigenori Matsushima2, Nagato Kuriyama3, Kazunari Ishii4, Etsuro Mori5, Kei Yamada2, Toshiki Mizuno1, Takahiko Tokuda1,6.   

Abstract

OBJECTIVE: The gold standard for the diagnosis of idiopathic normal pressure hydrocephalus (iNPH) is the CSF removal test. For elderly patients, however, a less invasive diagnostic method is required. On MRI, high-convexity tightness was reported to be an important finding for the diagnosis of iNPH. On SPECT, patients with iNPH often show hyperperfusion of the high-convexity area. The authors tested 2 hypotheses regarding the SPECT finding: 1) it is relative hyperperfusion reflecting the increased gray matter density of the convexity, and 2) it is useful for the diagnosis of iNPH. The authors termed the SPECT finding the convexity apparent hyperperfusion (CAPPAH) sign.
METHODS: Two clinical studies were conducted. In study 1, SPECT was performed for 20 patients suspected of having iNPH, and regional cerebral blood flow (rCBF) of the high-convexity area was examined using quantitative analysis. Clinical differences between patients with the CAPPAH sign (CAP) and those without it (NCAP) were also compared. In study 2, the CAPPAH sign was retrospectively assessed in 30 patients with iNPH and 19 healthy controls using SPECT images and 3D stereotactic surface projection.
RESULTS: In study 1, rCBF of the high-convexity area of the CAP group was calculated as 35.2–43.7 ml/min/100 g, which is not higher than normal values of rCBF determined by SPECT. The NCAP group showed lower cognitive function and weaker responses to the removal of CSF than the CAP group. In study 2, the CAPPAH sign was positive only in patients with iNPH (24/30) and not in controls (sensitivity 80%, specificity 100%). The coincidence rate between tight high convexity on MRI and the CAPPAH sign was very high (28/30).
CONCLUSIONS: Patients with iNPH showed hyperperfusion of the high-convexity area on SPECT; however, the presence of the CAPPAH sign did not indicate real hyperperfusion of rCBF in the high-convexity area. The authors speculated that patients with iNPH without the CAPPAH sign, despite showing tight high convexity on MRI, might have comorbidities such as Alzheimer’s disease.

Entities:  

Keywords:  123I-IMP = 123I-iodoamphetamine; 123I-IMP SPECT; ARG = autoradiography; CAP = patients with the CAPPAH sign; CAPPAH = convexity apparent hyperperfusion; CBF = cerebral blood flow; DESH = disproportionately enlarged subarachnoid space hydrocephalus; FAB = Frontal Assessment Battery; MMSE = Mini–Mental State Examination; NCAP = patients without the CAPPAH sign; ROI = region of interest; SEE = stereotactic extraction estimation; SSP = stereotactic surface projection; TMT-A = Trail Making Test A; TUG = Timed Up and Go; cerebral blood flow; convexity apparent hyperperfusion sign; iNPH = idiopathic normal pressure hydrocephalus; iNPHGS = iNPH Grading Scale; idiopathic normal pressure hydrocephalus; rCBF = regional CBF

Mesh:

Substances:

Year:  2018        PMID: 29547088     DOI: 10.3171/2017.9.JNS171100

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  7 in total

Review 1.  Interplay between vascular hemodynamics and the glymphatic system in the pathogenesis of idiopathic normal pressure hydrocephalus, exploring novel neuroimaging diagnostics.

Authors:  Sauson Soldozy; Kaan Yağmurlu; Jeyan Kumar; Turki Elarjani; Josh Burks; Aria Jamshidi; Evan Luther; Kenneth C Liu; Carolina G Benjamin; Robert M Starke; Min S Park; Hasan R Syed; Mark E Shaffrey; Ricardo J Komotar
Journal:  Neurosurg Rev       Date:  2021-11-13       Impact factor: 3.042

2.  Apoplexy in sellar metastasis from papillary thyroid cancer: A case report and literature review.

Authors:  Masahiro Hirayama; Atsushi Ishida; Naoko Inoshita; Hideki Shiramizu; Haruko Yoshimoto; Masataka Kato; Satoshi Tanaka; Seigo Matsuo; Nobuhiro Miki; Masami Ono; Shozo Yamada
Journal:  Surg Neurol Int       Date:  2022-06-17

3.  Ventriculomegaly Is the First Brain Morphological Change in Prodromal Idiopathic Normal Pressure Hydrocephalus.

Authors:  Tomoko Totsune; Toru Baba; Ken-Ichi Nagamatsu; Atsushi Takeda
Journal:  Mov Disord Clin Pract       Date:  2021-08-05

Review 4.  Diagnostic imaging of dementia with Lewy bodies, frontotemporal lobar degeneration, and normal pressure hydrocephalus.

Authors:  Kazunari Ishii
Journal:  Jpn J Radiol       Date:  2019-09-23       Impact factor: 2.374

5.  Guidelines for Management of Idiopathic Normal Pressure Hydrocephalus (Third Edition): Endorsed by the Japanese Society of Normal Pressure Hydrocephalus.

Authors:  Madoka Nakajima; Shigeki Yamada; Masakazu Miyajima; Kazunari Ishii; Nagato Kuriyama; Hiroaki Kazui; Hideki Kanemoto; Takashi Suehiro; Kenji Yoshiyama; Masahiro Kameda; Yoshinaga Kajimoto; Mitsuhito Mase; Hisayuki Murai; Daisuke Kita; Teruo Kimura; Naoyuki Samejima; Takahiko Tokuda; Mitsunobu Kaijima; Chihiro Akiba; Kaito Kawamura; Masamichi Atsuchi; Yoshihumi Hirata; Mitsunori Matsumae; Makoto Sasaki; Fumio Yamashita; Shigeki Aoki; Ryusuke Irie; Hiroji Miyake; Takeo Kato; Etsuro Mori; Masatsune Ishikawa; Isao Date; Hajime Arai
Journal:  Neurol Med Chir (Tokyo)       Date:  2021-01-15       Impact factor: 1.742

6.  Neuroimaging Findings in a Patient with Anti-IgLON5 Disease: Cerebrospinal Fluid Dynamics Abnormalities.

Authors:  Daniele Urso; Roberto De Blasi; Antonio Anastasia; Valentina Gnoni; Valentina Rizzo; Salvatore Nigro; Benedetta Tafuri; Carlo Maria Iacolucci; Chiara Zecca; Maria Teresa Dell'Abate; Francesca Andreetta; Giancarlo Logroscino
Journal:  Diagnostics (Basel)       Date:  2022-03-30

7.  Mantle cell lymphoma with aseptic meningitis mimicking hydrocephalus on brain imaging.

Authors:  Satoshi Samizo; Katsuya Furukawa; Hiroyuki Umegaki
Journal:  Nagoya J Med Sci       Date:  2022-05       Impact factor: 0.794

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.